



miRNA-375 a Sensor of Glucotoxicity Is Altered in the Serum of Children with Newly Diagnosed Type 1 Diabetes

Lucien Marchand, Audrey Jalabert, Emmanuelle Fouilloux-Meugnier, Kathleen van Den Hende, Nicole Fabien, Marc Nicolino, Anne-Marie Madec, Charles Thivolet, Sophie Rome

► To cite this version:

Lucien Marchand, Audrey Jalabert, Emmanuelle Fouilloux-Meugnier, Kathleen van Den Hende, Nicole Fabien, et al.. miRNA-375 a Sensor of Glucotoxicity Is Altered in the Serum of Children with Newly Diagnosed Type 1 Diabetes. Journal of diabetes research, 2016, 2016, pp.1-7. 10.1155/2016/1869082 . hal-01850359

HAL Id: hal-01850359

<https://hal.science/hal-01850359>

Submitted on 27 May 2020

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Research Article

miRNA-375 a Sensor of Glucotoxicity Is Altered in the Serum of Children with Newly Diagnosed Type 1 Diabetes

Lucien Marchand,^{1,2} Audrey Jalabert,¹ Emmanuelle Meugnier,¹
Kathleen Van den Hende,³ Nicole Fabien,⁴ Marc Nicolino,^{1,3} Anne-Marie Madec,¹
Charles Thivolet,^{1,2} and Sophie Rome¹

¹CarMeN Laboratory (INSERM 1060, INRA 1362, INSA), Lyon-Sud Faculty of Medicine, University of Lyon,
Chemin du Grand Revoyet, 69600 Oullins, France

²Hospices Civils de Lyon, Lyon-Sud Hospital, Department of Diabetology and Endocrinology, 69495 Pierre-Bénite, France

³Hospices Civils de Lyon, Department of Pediatric Endocrinology, Femme-Mère-Enfant Hospital, 69500 Bron, France

⁴Hospices Civils de Lyon, INSERM U851, Lyon-Sud Hospital, Department of Immunology, 69495 Pierre-Bénite, France

Correspondence should be addressed to Sophie Rome; srome@univ-lyon1.fr

Received 18 January 2016; Revised 11 March 2016; Accepted 19 April 2016

Academic Editor: Paolo Fiorina

Copyright © 2016 Lucien Marchand et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Background. The use of miRNAs as biomarkers for Type 1 Diabetes (T1D) risk is attractive as T1D is usually diagnosed in front of acute symptoms. As miR-375 is highly expressed in the endocrine pancreas, we postulated that its circulating level might reflect beta cell alterations and might be altered in the blood of T1D patients recently diagnosed. **Methods.** Sera were obtained from 22 T1D children at onset of the disease, before subcutaneous insulin treatment, and from 10 nondiabetic pediatric controls. MiR-375 seric level was quantified by stem-loop RT-PCR-based assay. MiRNAs regulations in isolated human islets in response to high glucose concentrations were determined by TaqMan Low-Density Array. **Results.** The abundance of miR-375, among the 410 miRNAs detected in human islets, mirrored its well-established role in rodent islet biology. Upregulated miRNAs targeted genes involved in islet homeostasis and regulation of beta cell mass. Downregulated miRNAs, including miR-375, were involved in pancreas secretion and protein turnover. Seric level of miR-375 was lower in T1D children versus age-matched controls, without any correlations with HbA_{1c}, glycaemia, and number of autoantibodies. **Conclusion.** Altered circulating level of miR-375 at onset of T1D might be a general biomarker of metabolic alterations and inflammation associated with the disease.

1. Introduction

Type 1 diabetes (T1D) affects approximately 10% of adults diagnosed with diabetes [1]. First described as an autoimmune disease in which autoreactive T cells destroy insulin-producing beta cells of the pancreas, it is now recognized that several potential environmental factors, including the possible role of chronic viral infections, can be causative agents [2]. Although it is important to diagnose diabetes as early as possible in order to prevent ketoacidosis, circulating autoantibodies against beta cell autoantigens are currently the only biomarkers available in the clinics. However, the presence of these autoantibodies does not always correlate with the loss of beta cell mass as positive individuals do not

always develop T1D [3]. In addition, recent access to pancreatic tissue from the nPOD biobank has allowed showing the existence of a significant amount of remaining beta cells in the pancreas of T1D patients several years after clinical diagnosis [4, 5]. Therefore, identification of new biomarkers in the early phases of the disease is necessary and represents an important challenge, as the disease is largely silent in its initial stages.

In that context, blood miRNA levels represent a new class of biomarkers for diagnosis and prognosis of several diseases and have emerged as new targets for treatments and interventions. MiRNAs are small noncoding RNAs of 19–22 nucleotides which act as negative regulators of gene expression, mainly at the posttranscriptional level [6]. Studies in the last 5 years have demonstrated that miRNAs are not

TABLE 1: Clinical and metabolic characteristics of T1D children and of age-matched controls.

Parameters	Children with newly diagnosed T1D (<i>n</i> = 22)	Controls (<i>n</i> = 10)
Age (years)	9.81 ± 3.59	9.91 ± 2.34
Gender (M/F)	14/8	5/5
Glucose level during blood collection (mmol/L)	11.45 ± 3.48	4.0 ± 0.5*
HbA1c (%)	11.82 ± 2.15	4.5 ± 0.5*
BMI (kg/m ²)	15.80 ± 2.49	ND
Number of patients with anti-GAD aAbs	<i>N</i> = 14	ND
Number of patients with anti-IA2 aAbs	<i>N</i> = 15	ND
Number of patients with anti-ZNT8 aAbs	<i>N</i> = 17	ND

* *p* < 0.05 T1D versus controls.

aAbs: autoantibodies.

only found intracellularly but are also detected outside cells in various body fluids [7]. Remarkably, it has been found that some circulating blood miRNA levels are proportional to the degree of severity of the pathology such as drug-induced liver injury [8], cardiovascular infection [9], cancer [10], Alzheimer's [11], inflammation [12], and metabolic diseases (obesity and type 2 diabetes [13]). In the context of T1D, 12 miRNAs were found more concentrated in sera from children and adolescents with newly diagnosed T1D compared to sera from age-matched controls [14]. Among them, an association of miR-25 with improved glycemic control and better residual beta cell function was found, suggesting that this miRNA could be used during early and intensive management of newly diagnosed diabetes to improve blood glucose control and reduce microvascular complications [14]. Another recent study involving pediatric T1D patients with duration of disease longer than 1 year revealed a significant deregulation of miR-21, miR-126, and miR-210 in plasma and urinary samples. As dysregulation of these miRNAs has been shown in type 2 diabetes or renal diseases, their alterations in plasma of T1D patients may indicate ongoing endothelial dysfunction or preclinical kidney disease [15]. Taken together, these 2 studies provided a proof of concept that the concentration of circulating miRNAs was affected in both newly or long-term diagnosed T1D already under insulin treatment. However, no data indicate whether these blood miRNAs could be monitoring the course of the disease in the early steps.

MiR-375 is highly expressed in the endocrine pancreas (islet beta cells and nonbeta cells) and was first cloned from an insulin-secreting cell line MIN6B1 [16]. In vitro studies have shown that miR-375 is involved in islet development [17], inhibits insulin gene expression in response to glucose [16], and regulates voltage-gated Na(+) channels and the exocytotic machinery [18]. *KO-miR-375* mice are hyperglycemic and have elevated plasma glucagon levels [17]. Based on these data, we hypothesized that the level of miR-375 could be altered in the blood of T1D patients of recent onset. Thus, in this study, we have validated this hypothesis by quantifying the level of miR-375 in the sera from children at onset of T1D (before subcutaneous insulin treatment) and in age-matched controls. We have also analyzed the global miRNA profile in human islets exposed to high glucose concentrations to determine whether glucotoxicity might affect the level of miR-375 in beta cells.

2. Methods

2.1. Patients. Sera from 22 children at onset of T1D within two days after clinical diagnosis (immediate insulin-requiring diabetes with at least one positive autoantibody) and before subcutaneous insulin treatment and sera from 10 control subjects (nonobese and nondiabetic child) were collected in 2014 at the Pediatric Endocrinology Department (Hospital Femme-Mère-Enfant, Bron, France). Exclusion criteria for both groups were any febrile illness during the last month and chronic inflammatory disease. Age, gender, BMI, glycemia at discovery, and HbA1c were recorded. Blood samples were taken during usual biological monitoring. All patients and controls provided written informed consent for the collection of samples and subsequent analysis. Clinical and biological characteristics of T1D children and controls are summarized in Table 1.

2.2. Serum Sampling. Whole blood was collected and allowed to clot for 30 min at room temperature. Clot was removed by centrifuging at 2,000 ×g for 10 minutes in a refrigerated centrifuge. The resulting supernatant designated as serum was transferred into a clean polypropylene tube using a Pasteur pipette. Autoantibodies to glutamic acid decarboxylase (GAD), islet-antigen 2 (IA2), and zinc transporter 8 (ZnT8) were quantified by ELISA (Medizym®, Medipan GmbH, Dahlewitz, Germany) and were considered to be positive for titers above 5, 10, and 15 UI/mL, respectively.

2.3. Serum Hemolysis Quantification. Hemolysis of sera (80 µL) was evaluated by spectrophotometry (450 nm) (Biochemical Department, Lyon-Sud Hospital). None of the 32 serum samples were hemolysed.

2.4. Culture of Human Islets. Human islets were obtained in collaboration with the Geneva University Hospitals Cell Isolation And Transplantation Center (Switzerland) and from the Unité Mixte de Thérapie Cellulaire et Tissulaire de Grenoble (France) Characteristics of the donors are summarized in Table 2. The use of human islet preparations for experimental research was approved by the Institutional Review Board for Clinical Research of the Departments of Neurology, Dermatology, Anesthesiology and Surgery of the University Hospital of Geneva (CER number 05–028). Islets (purity at

TABLE 2: Characteristics of the islet donors.

Replicate ID	Age of the donors	Gender	BMI	% of beta cells in islets
P729	54	F	30.5	70
P733	23	M	26.0	76
P819	59	F	20.3	90

least 70%) were processed as described previously [19] and cultured in a DMEM medium containing 5.5 mM or 16.7 mM glucose and 5% (vol./vol.) FBS (PAA Laboratories GmbH).

2.5. RNA Extraction from Human Serum. 150 μ L of serum was transferred in an Eppendorf tube and mixed with 450 μ L of TRIzol® LS specially designed for liquid samples (Life Technologies). Then, 150 μ L of chloroform (Sigma Aldrich) was added and 20 fmol of synthetic cel-miR-39 (UCAC-CGGGUGUAAAUCAGCUUG) was spiked into the serum (Qiagen). Cel-miR-39 from *C. elegans* has no homology with human miRNAs. It is added at the beginning of the extraction as control for RNA extraction. The solution was vortexed to obtain a homogenous phase. Tubes were centrifuged for 20 minutes at 12,000 rpm (4°C). A fixed volume of aqueous phase (250 μ L) was mixed with 250 μ L isopropanol and 2 μ L glycogen (Roche Diagnostic) and tubes were centrifuged for 30 minutes at 13,000 rpm. The pellet was washed with ethanol 75% and dried and the pellet resuspended in 16 μ L RNase-free water.

2.6. Amplification of Seric miR-375 by qRT-PCR. A fixed volume of total RNA (5 μ L for miR-375 and 1 μ L for miR-39) was used for reverse transcription (RT) reaction. RT reactions were realized with 0.15 μ L dNTP, 1.5 μ L buffer (10x), 9 μ L RNase-free water, 0.2 μ L RNase inhibitor, 1 μ L multiscribe RTase, and 3 μ L of specific miR-375 RT primers (Life Technologies). RT reactions were realized at 16°C for 30 minutes, 42°C for 30 minutes, and 85°C for 5 minutes using a PTC-100 Peltier thermal cycler (Mj Research). At the end of the RT reaction, samples were diluted to 1/10 with RNase-free water for PCR.

The TaqMan miR-375 assay (Life Technologies) was used to quantify miR-375. 5 μ L of RT reactions was mixed with 10 μ L of TaqMan Universal PCR master mix ($\times 2$, (Life Technologies)), 4 μ L of RNase-free water, and 1 μ L of TaqMan miRNA Assay ($\times 20$, (Life Technologies)). PCR was performed on a Rotor Gene thermocycler at 95°C for 10 minutes, followed by 40 cycles of 95°C for 15 seconds and 60°C for 60 seconds. All samples were run in duplicate; Ct (cycle threshold) values were automatically determined by the software.

2.7. Statistical Analysis. Analyses were performed with R software. *t*-tests were used for quantitative variable. Pearson's correlations between miRNA levels and clinical or metabolic parameters were calculated.

2.8. miRNA Profiling by qRT-PCR in Human Islets. Total RNA was extracted from 3 independent human islet preparations by using TriPure Isolation Reagent (Roche Applied

Science, France). RNA concentration was measured with a NanoDrop spectrophotometer, ND-1000 (Thermo-Fisher, Waltham, MA, USA). Profiling of miRNAs was determined using the TaqMan Low-Density Array cards A and B (Applied Biosystems). Briefly, total RNA was reverse transcribed using TaqMan miRNA Reverse Transcription Kit (Applied Biosystems) in combination with the stem-loop Megaplex primers in 7.5 μ L. Next, 2.5 μ L of RT was mixed with 2.5 μ L of Megaplex PreAmp Primers and 12.5 μ L TaqMan PreAmp Master Mix in a 25 μ L PCR reaction and preamplified. The preamplified cDNA was then diluted with 0.1x TE (pH 8.0) to 100 μ L. Nine μ L of diluted cDNA solution was used for qRT-PCR runs. qRT-PCR was performed on a 7900HT thermocycler (Applied Biosystems) using the manufacturer's recommended cycling conditions: 50°C for 2 min and 95°C for 10 min and then 40 cycles at 95°C for 15 s and 60°C for 1 min. Data were recorded at the end of each cycle. Cycle threshold (Ct) values were calculated with the SDS software using automatic baseline settings with assigned minimum Ct threshold of 0.2. Ct values > 40 were excluded from data analysis. Each card included 3 miRNA endogenous controls and one miRNA assay not related to human. For each card, quality controls were performed on the raw data by checking internal controls and using box plot diagrams. Since the currently used normalization small RNA mammU6 plotted in each card was not stably expressed in our different samples, we have used the mean expression level of all fully observed miRNAs for normalization [20]. Group comparisons were made by using student's *t*-test ($p < 0.05$) on normalized data, to select the differentially expressed miRNAs.

3. Results

This study aimed to evaluate whether the circulating level of miR-375 was altered at onset of T1D. Therefore, we have quantified miR-375 in sera from children population at onset of T1D (immediate insulin-requiring diabetes with at least one positive autoantibody) before subcutaneous insulin treatment. T1D children had elevated HbA1c ($11.82\% \pm 2.15$) and had at least one positive autoantibody for GAD, IA-2, and/or ZNT8, confirming an ongoing autoimmunity to beta cells. As shown in Figure 1, the level of miR-375 was significantly lower in the sera of the 22 T1D children than in the sera of the 10 healthy controls (mean normalized Ct values: 30.61 ± 0.20 versus 29.02 ± 0.57 , $p = 0.008$). We did not find any association between miR-375 serum concentration and HbA1c, glycaemia, and the number of autoantibodies (Table 3).

Then, we have analyzed the global miRNA profile in human islets exposed to high glucose concentrations to determine whether glucotoxicity might affect the level of




FIGURE 1: Quantification of miR-375 in sera of newly diagnosed T1D children. Data are expressed as Ct values. The Ct is defined as the number of cycles required for the fluorescent signal to cross the threshold (i.e. exceeding background level). Ct levels are inversely proportional to the amount of target nucleic acid in the sample (i.e. the lower the Ct level, the greater the amount of target nucleic acid in the sample). To analyze individual qPCR data, we first controlled the quality of RNA extraction by quantifying Cel-miR-39 (spike). The following formula was used for normalizing the Ct values of miR-375 in all sera samples: raw Ct value – [(spike-in average Ct value of sample) – (median spike-in Ct)]. Data are expressed as mean values \pm SEM.

TABLE 3: Correlations between miR-375 concentration in sera and clinical and biological parameters of the T1D patients.

Variables	Pearson coefficient correlation	<i>p</i> values
Age	0.117	0.665
Gender	0.006	0.981
Glycaemia at discovery	0.212	0.430
HbA1c	0.236	0.378
BMI	0.187	0.487
Number of positive antibodies	0.130	0.629

BMI: body mass index.

miR-375 in beta cells. As shown in supplementary Table 1 in Supplementary Material available online at <http://dx.doi.org/10.1155/2016/1869082>, 410 miRNAs were detected in human islets and miR-375 was the most expressed one. Nine miRNAs (miR-519a, miR-212, miR-320b, miR-27a*, miR-30d*, miR-23a*, miR-30d*, miR-23a*, and miR-10a*) and 5 miRNAs (miR-375, miR-485-3p, miR-23b, miR-485-3p, miR-23b, miR-627, and miR-1197) were up- or downregulated by glucose, respectively (Figure 2). miR-375 and miR-212 had been previously identified as regulated by glucose in rat islets [21]. Upregulated miRNAs targeted important signaling pathways for islet homeostasis and regulation of beta cell mass. They were also involved in viral infections and cancer development (see Box 1).

Downregulated miRNAs were involved in pancreas secretion and in protein processing and degradation (see Box 1). All these functions are important for insulin secretion. In addition, downregulated miRNAs targeted genes involved in biotin metabolism and glycosphingolipid biosynthesis, two functions affected in T1D patients [22, 23]. Interestingly, miR-375 was downregulated in human islets exposed to high glucose concentrations, suggesting a close relationship between miR-375 and glucose (Figure 2).

4. Discussion

The contribution of miRNAs to the development of human T1D has been largely unexplored. More particularly, their use as biomarkers to monitor the fate and/or function of the pancreatic beta cells is attractive. In this study, we have found that miR-375 is strongly decreased in the serum of newly identified T1D children, before the initiation of subcutaneous insulin treatment. These data are in agreement with previous studies on animal models showing that plasma miR-375 is altered in streptozotocin-treated mice prior to the onset of hyperglycemia or 2 weeks before diabetes onset in nonobese diabetic mice [24]. As miR-375 regulates insulin secretion and beta cell mass [16, 17], we postulated that its expression might be altered in beta cells concomitantly to its circulating level. In order to further interpret our data, we have determined, for the first time, the miRNA profile of human islets incubated with high glucose concentrations. The abundance of miR-375 in the miRNA profile of human islets found in this study confirmed its critical role in human pancreatic beta cells [25],




FIGURE 2: MiRNAs are regulated in human islet in response to glucose. miRNA regulations in human islets exposed to 16.7 mM versus 5.5 mM for 24 h (see Table 2). Data are expressed as mean of 3 biological replicates \pm SEM. Each miRNA was normalized to the geometric mean of all miRNAs expressed in all replicates.

mirroring its well-established role in rodent islet biology [16]. We found that miR-375 was downregulated in human islets treated with high glucose concentrations. Decreased functional beta cell mass is a hallmark of both type 1 diabetes and type 2 diabetes (T2DM) and, interestingly, obese and pre-T2DM patients have also decreased level of blood miR-375 compared to healthy controls [26–28]. On the contrary, T1D and T2DM patients with controlled glycemia have increased circulating levels of miR-375 [29–31]. As we have previously found that beta cells can release miR-375 in extracellular environment [32], our data could suggest a possible link between circulating miR-375 levels and early alterations of islet integrity and functionality reflecting glucotoxicity in humans. However, this hypothesis has to be temporized as it is likely that only a small proportion ($\approx 1\%$) of circulating miR-375 is originated from beta cells, at least in mice [33]. Extracellular miR-375 pool is very heterogeneous and various cells and tissues can release this miRNA. In human, miR-375 is also strongly expressed in GI-tract, adipose tissue, liver, adrenal, and brain [34]. Thus, altered circulating level of miR-375 at the beginning of T1D development could be also a general marker of metabolic alterations and/or inflammation associated with the disease, in addition to being representative of alterations of islet physiology. Indeed, most individuals affected by T1D exhibit multiple features associated with impaired B- and T-cell functions [35–37]. Presently, islet transplantation offers a potential cure for T1D [35]. Beside beta cell exhaustion and/or apoptosis, recurrent autoimmune damage creates a serious challenge to successful long-term islet transplantation [38]. The analysis of miRNAs changes (both in pancreas and blood) may help to find early biomarkers for beta cell damage.

miR-375 was also predicted to regulate pathways involved in viral infections in human islets. We have previously shown that circulating whole-blood cells from newly diagnosed patients with T1D, as well as autoantibody-positive first degree relatives, had increased expression of IFN-induced genes [39]. This fits well with the current knowledge of disease pathogenesis with the possible role played by viral infections [40]. Therefore, in addition to hyperglycemia and inflammation, expression of miR-375 might be also influenced by environmental factors such as viruses. In line with this hypothesis, miR-375 concentration in serum is modified in individuals infected with hepatitis B virus [41].

Taken together, our data demonstrated that miR-375 might be a potential biomarker at the onset of T1D that is also modulated in human islets exposed *in vitro* to glucose. It remains to determine whether this miRNA reflects only metabolic disturbances observed during T1D or also reflects chronic processes leading to inflammation of the pancreas and beta cell loss. Moreover, quantification of circulating miR-375 in prediabetic individuals is now necessary to validate the role of this new biomarker during the early phases of the disease.

Competing Interests

The authors declare that there are no competing interests associated with this paper.

Authors' Contributions

All the authors read and approved the final paper.

KEGG pathways targeted by downregulated miRNAs
 Adherence junction (hsa04520)
 Biotin metabolism (hsa00780)
 Glycosphingolipid biosynthesis, lacto- and neolactoseries (hsa00601)
 Pancreatic secretion (hsa04972)
 Protein processing in endoplasmic reticulum (hsa04141)
 Ubiquitin mediated proteolysis (hsa04120)
 Rap1 signaling pathway (hsa04015)
 Thyroid hormone signaling pathway (hsa04919)

KEGG pathways targeted by upregulated miRNAs
 Axon guidance (hsa04360)
 Mucin type O-glycan biosynthesis (hsa00512)
 Valine, leucine, and isoleucine biosynthesis (hsa00290)
 Circadian rhythm (hsa04710)
 ECM-receptor interaction (hsa04512)
 Gap junction (hsa04540)
 Focal adhesion (hsa04510)
 Estrogen signaling pathway (hsa04915)
 Hippo signaling pathway (hsa04390)
 FoxO signaling pathway (hsa04068)
 mTOR signaling pathway (hsa04150)
 Wnt signaling pathway (hsa04310)
 Signaling pathways regulating pluripotency of stem cells (hsa04550)
 TGF-beta signaling pathway (hsa04350)
 PI3K-Akt signaling pathway (hsa04151)
 Prion diseases (hsa05020)
 Viral carcinogenesis (hsa05203)
 Hepatitis B (hsa05161)
 Chronic myeloid leukemia (hsa05220)
 Glioma (hsa05214)
 Melanoma (hsa05218)
 Non-small cell lung cancer (hsa05223)
 Pancreatic cancer (hsa05212)
 Pathways in cancer (hsa05200)
 Prostate cancer (hsa05215)
 Proteoglycans in cancer (hsa05205)
 Renal cell carcinoma (hsa05211)
 Thyroid cancer (hsa05216)
 Transcriptional misregulation in cancer (hsa05202)

Box 1: Significant KEGG pathways collectively targeted by miRNAs regulated by glucose in human islets, from DIANA miRPath v3.0 (<http://snf-515788.vm.okeanos.grnet.gr/dianauniverse/index.php?r=mirpath>).

Acknowledgments

Professor Charles Thivolet belongs to the nPOD network, a collaborative diabetes research project sponsored by the Juvenile Diabetes Research Foundation (JDRF) and NIH. In this network, Pr. Charles Thivolet is involved in the project “Novel Biomarkers.” This work was supported by a grant from the Association for Diabetes Research (ARD).

References

- [1] M. A. Atkinson, G. S. Eisenbarth, and A. W. Michels, “Type 1 diabetes,” *The Lancet*, vol. 383, no. 9911, pp. 69–82, 2014.
- [2] B. Buckingham, R. W. Beck, K. J. Ruedy et al., “Effectiveness of early intensive therapy on β -cell preservation in type 1 diabetes,” *Diabetes Care*, vol. 36, no. 12, pp. 4030–4035, 2013.
- [3] P. In't Veld, “Insulinitis in human type 1 diabetes: a comparison between patients and animal models,” *Seminars in Immunopathology*, vol. 36, no. 5, pp. 569–579, 2014.
- [4] A. Willcox, S. J. Richardson, A. J. Bone, A. K. Foulis, and N. G. Morgan, “Analysis of islet inflammation in human type 1 diabetes,” *Clinical & Experimental Immunology*, vol. 155, no. 2, pp. 173–181, 2009.
- [5] M. Campbell-Thompson, C. Wasserfall, J. Kaddis et al., “Network for Pancreatic Organ Donors with Diabetes (nPOD): developing a tissue biobank for type 1 diabetes,” *Diabetes/Metabolism Research and Reviews*, vol. 28, no. 7, pp. 608–617, 2012.
- [6] D. P. Bartel, “MicroRNAs: genomics, biogenesis, mechanism, and function,” *Cell*, vol. 116, no. 2, pp. 281–297, 2004.
- [7] J. A. Weber, D. H. Baxter, S. Zhang et al., “The microRNA spectrum in 12 body fluids,” *Clinical Chemistry*, vol. 56, no. 11, pp. 1733–1741, 2010.

- [8] K. Wang, S. Zhang, B. Marzolf et al., "Circulating microRNAs, potential biomarkers for drug-induced liver injury," *Proceedings of the National Academy of Sciences of the United States of America*, vol. 106, no. 11, pp. 4402–4407, 2009.
- [9] L. N. L. Van Aelst and S. Heymans, "MicroRNAs as biomarkers for ischemic heart disease," *Journal of Cardiovascular Translational Research*, vol. 6, no. 4, pp. 458–470, 2013.
- [10] M. Ferracin, A. Veronese, and M. Negrini, "Micromarkers: miRNAs in cancer diagnosis and prognosis," *Expert Review of Molecular Diagnostics*, vol. 10, no. 3, pp. 297–308, 2010.
- [11] H. Geekiyanage, G. A. Jicha, P. T. Nelson, and C. Chan, "Blood serum miRNA: non-invasive biomarkers for Alzheimer's disease," *Experimental Neurology*, vol. 235, no. 2, pp. 491–496, 2012.
- [12] R. M. O'Connell, D. S. Rao, and D. Baltimore, "microRNA regulation of inflammatory responses," *Annual Review of Immunology*, vol. 30, pp. 295–312, 2012.
- [13] A. Villard, L. Marchand, C. Thivolet, and S. Rome, "Diagnostic value of cell-free circulating microRNAs for obesity and type 2 diabetes: a meta-analysis," *Journal of Molecular Biomarkers & Diagnosis*, vol. 6, article 251, 2015.
- [14] L. B. Nielsen, C. Wang, K. Sørensen et al., "Circulating levels of microRNA from children with newly diagnosed type 1 diabetes and healthy controls: evidence that miR-25 associates to residual beta-cell function and glycaemic control during disease progression," *Experimental Diabetes Research*, vol. 2012, Article ID 896362, 7 pages, 2012.
- [15] J. Osipova, D.-C. Fischer, S. Dangwal et al., "Diabetes-associated microRNAs in pediatric patients with type 1 diabetes mellitus: a cross-sectional cohort study," *Journal of Clinical Endocrinology and Metabolism*, vol. 99, no. 9, pp. E1661–E1665, 2014.
- [16] M. N. Poy, L. Eliasson, J. Krutzfeldt et al., "A pancreatic islet-specific microRNA regulates insulin secretion," *Nature*, vol. 432, no. 7014, pp. 226–230, 2004.
- [17] M. N. Poy, J. Hausser, M. Trajkovski et al., "miR-375 maintains normal pancreatic alpha- and beta-cell mass," *Proceedings of the National Academy of Sciences of the United States of America*, vol. 106, no. 14, pp. 5813–5818, 2009.
- [18] V. A. Salunkhe, J. L. S. Esguerra, J. K. Ofori et al., "Modulation of microRNA-375 expression alters voltage-gated Na⁺ channel properties and exocytosis in insulin-secreting cells," *Acta Physiologica*, vol. 213, no. 4, pp. 882–892, 2015.
- [19] J. Hoseki, R. Ushioda, and K. Nagata, "Mechanism and components of endoplasmic reticulum-associated degradation," *Journal of Biochemistry*, vol. 147, no. 1, pp. 19–25, 2010.
- [20] A. Deo, J. Carlsson, and A. Lindlöf, "How to choose a normalization strategy for miRNA quantitative real-time (qPCR) arrays," *Journal of Bioinformatics and Computational Biology*, vol. 9, no. 6, pp. 795–812, 2011.
- [21] J. L. S. Esguerra, C. Bolmeson, C. M. Cilio, and L. Eliasson, "Differential glucose-regulation of microRNAs in pancreatic islets of non-obese type 2 diabetes model Goto-Kakizaki rat," *PLoS ONE*, vol. 6, no. 4, Article ID e18613, 2011.
- [22] J. C. Coggeshall, J. P. Heggors, M. C. Robson, and H. Baker, "Biotin status and plasma glucose in diabetics," *Annals of the New York Academy of Sciences*, vol. 447, no. 1, pp. 389–392, 1985.
- [23] E. Boslem, P. J. Meikle, and T. J. Biden, "Roles of ceramide and sphingolipids in pancreatic β -cell function and dysfunction," *Islets*, vol. 4, no. 3, pp. 177–187, 2012.
- [24] S. Erener, M. Mojibian, J. K. Fox, H. C. Denroche, and T. J. Kieffer, "Circulating miR-375 as a biomarker of β -cell death and diabetes in mice," *Endocrinology*, vol. 154, no. 2, pp. 603–608, 2013.
- [25] M. van de Bunt, K. J. Gaulton, L. Parts et al., "The miRNA profile of human pancreatic islets and beta-cells and relationship to type 2 diabetes pathogenesis," *PLoS ONE*, vol. 8, no. 1, article e55272, 2013.
- [26] E. Flowers, G. Y. Won, and Y. Fukuoka, "MicroRNAs associated with exercise and diet: a systematic review," *Physiological Genomics*, vol. 47, no. 1, pp. 1–11, 2015.
- [27] L. Kong, J. Zhu, W. Han et al., "Significance of serum microRNAs in pre-diabetes and newly diagnosed type 2 diabetes: a clinical study," *Acta Diabetologica*, vol. 48, no. 1, pp. 61–69, 2011.
- [28] G. Carreras-Badosa, A. Bonmati, F. J. Ortega et al., "Altered circulating miRNA expression profile in pregestational and gestational obesity," *The Journal of Clinical Endocrinology & Metabolism*, vol. 100, no. 11, pp. E1446–E1456, 2015.
- [29] M. Latreille, K. Herrmanns, N. Renwick et al., "miR-375 gene dosage in pancreatic β -cells: implications for regulation of β -cell mass and biomarker development," *Journal of Molecular Medicine*, vol. 93, no. 10, pp. 1159–1169, 2015.
- [30] C. Higuchi, A. Nakatsuka, J. Eguchi et al., "Identification of circulating miR-101, miR-375 and miR-802 as biomarkers for type 2 diabetes," *Metabolism: Clinical and Experimental*, vol. 64, no. 4, pp. 489–497, 2015.
- [31] D. S. Karolina, A. Armugam, S. Tavintharan et al., "MicroRNA 144 impairs insulin signaling by inhibiting the expression of insulin receptor substrate 1 in type 2 diabetes mellitus," *PLoS ONE*, vol. 6, no. 8, Article ID e22839, 2011.
- [32] C. Guay, V. Menoud, S. Rome, and R. Regazzi, "Horizontal transfer of exosomal microRNAs transduce apoptotic signals between pancreatic beta-cells," *Cell Communication and Signaling*, vol. 13, no. 1, article 17, 2015.
- [33] M. Latreille, K. Herrmanns, N. Renwick et al., "miR-375 gene dosage in pancreatic β -cells: implications for regulation of β -cell mass and biomarker development," *Journal of Molecular Medicine*, vol. 93, no. 10, pp. 1159–1169, 2015.
- [34] Y. Liang, D. Ridzon, L. Wong, and C. Chen, "Characterization of microRNA expression profiles in normal human tissues," *BMC Genomics*, vol. 8, article 166, 2007.
- [35] P. Fiorina, A. M. J. Shapiro, C. Ricordi, and A. Secchi, "The clinical impact of islet transplantation," *American Journal of Transplantation*, vol. 8, no. 10, pp. 1990–1997, 2008.
- [36] M. J. I. Ansari, P. Fiorina, S. Dada et al., "Role of ICOS pathway in autoimmune and alloimmune responses in NOD mice," *Clinical Immunology*, vol. 126, no. 2, pp. 140–147, 2008.
- [37] P. Fiorina, A. Vergani, S. Dada et al., "Targeting CD22 reprograms B-cells and reverses autoimmune diabetes," *Diabetes*, vol. 57, no. 11, pp. 3013–3024, 2008.
- [38] A. Vergani, F. D'Addio, M. Jurewicz et al., "A novel clinically relevant strategy to abrogate autoimmunity and regulate alloimmunity in NOD mice," *Diabetes*, vol. 59, no. 9, pp. 2253–2264, 2010.
- [39] F. Reynier, A. Pachot, M. Paye et al., "Specific gene expression signature associated with development of autoimmune type-1 diabetes using whole-blood microarray analysis," *Genes and Immunity*, vol. 11, no. 3, pp. 269–278, 2010.
- [40] M. A. Atkinson, M. von Herrath, A. C. Powers, and M. Clare-Salzler, "Current concepts on the pathogenesis of type 1 diabetes—considerations for attempts to prevent and reverse the disease," *Diabetes Care*, vol. 38, no. 6, pp. 979–988, 2015.
- [41] L.-M. Li, Z.-B. Hu, Z.-X. Zhou et al., "Serum microRNA profiles serve as novel biomarkers for HBV infection and diagnosis of HBV-positive hepatocarcinoma," *Cancer Research*, vol. 70, no. 23, pp. 9798–9807, 2010.

